Charles Forsyth Email

Senior Director, Financial Planning and Analysis . Selecta Biosciences

Current Roles

Employees:
49
Revenue:
$7.6M
About
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTORâ„¢ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body's natural self-tolerance in autoimmune diseases. The company's first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi.
Selecta Biosciences Address
65 Grove Street
Watertown, MA
United States

Past Companies

Selecta BiosciencesSenior Director, Financial Planning and Analysis
EQRxDirector, Financial Planning and Analysis
Dicerna Pharmaceuticals, Inc.Director, R&D Financial and Strategic Planning

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.